Physicians and patients have long been aware of skin lesions at the sites of insulin injections, referred to as lipodystrophy that can present as lipoatrophy (LA) or lipohypertrophy (LH).
However, the reported prevalence of these different skin lesions varies widely, emphasizing the need for a correct identification method. In this short review we discuss LA and LH and also take into account other skin lesions, such as bruising, as well as different needle injuries, including those associated with the subcutaneous injection of pegvisomant (a drug aimed at counteracting the high levels of growth hormone associated with acromegaly), long-acting exenatide (a glucagon-like peptide-1 receptor agonist), and anti-tumor necrosis factor-alpha biologic agents (used against Crohn's disease). In these latter cases specific studies are warranted to understand the pathophysiological background and possible prevention. However, the most common lesion is still insulin injection site-related LD, so a strong effort has to be made to avoid the confusion generated by previously misleading classifications which were barely able to reliably distinguish between LA and LH. 
CLINICAL CONSEQUENCES OF LIPODYSTROPHIES
A missed diagnosis of LD may have major clinical consequences. The injection of insulin into parts of the body affected by LD may cause wide glycemic oscillations, including inappropriately high glucose levels and a high rate of unexplained hypoglycemic episodes, both of which are scarcely responsive even large changes in insulin dose [1, 8] . Programs aimed specifically at educating patients with LD on proper injection techniques has proven to be effective in significantly reducing glucose oscillations [9] .
Despite LH and LA on occasion being used improperly as synonyms [3] , we suggest that the two concepts be kept separate.
Most studies suggest that insulin absorption at areas affected by LH may be both delayed and erratic, leading to the need for ever increasing doses of insulin and worsening metabolic control [10] [11] [12] [13] [14] . This in turn causes unacceptable glucose oscillations due to a high rate of serious hypoglycemic episodes followed by rebound glucose spikes whenever patients suddenly switch from affected injection sites to normal ones. Under these conditions, the economic burden of the disease increases for both patients and the healthcare system. Therefore, it is crucial that as many areas affected by LH as possible are systematically identified in order to educate patients on good insulin injection habits. The reported prevalence of LH in patients receiving insulin injections varies widely in published studies [6] , possibly due to the lack of a well-structured diagnostic flow-chart despite the world-wide availability of suitable ultrasound and radiological methods [1, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . We recently published a methodological paper on a palpation technique that enables the clinician to identify skin lipohypertrophic lesions in diabetic patients receiving insulin [6] . We therefore propose that diabetes teams be formed at medical institutions which would systematically follow that simple procedure we describe for the diagnosis of LH at all insulin injection sites and then implement and hopefully progressively refine this procedure in large-scale studies. In particular, unexplained variations in glucose levels and/or unexplained hypoglycemic episodes may alert healthcare providers to look for LH in diabetic patients receiving insulin injections.
BRUISING
Another original aspect of insulin injection-related skin lesions is bruising at the level of the injection site, as shown in Fig. 1 .
Bruising is mentioned in several published studies on insulin injections [25] [26] [27] [28] . It is a problematic side-effect of insulin injections which disturbs diabetic patients due to the resulting blemishes, for which there are as yet no solutions. Unfortunately, in terms of both patient and healthcare provider perspectives, injection-related problems negatively affect the overall number of shots diabetic patients are willing to take [28] . In fact, in some studies one-half of the patients reported mentioning
injection-related problems to their healthcare providers who were unable to resolve the associated pain and bruising [28, 29] .
In a series of 780 insulin-treated adults with type 2 (n = 556) or type 1 (n = 223) diabetes mellitus on a multiple daily injection regimen (4 shots/day), we identified 46.2% of patients had areas affected by LH, with a mean lesion diameter of 4.8 ? 3.1 cm, but LA was quite uncommon (3.2%) (unpublished data). In this same series, 33.2% of patients showed bruising, either associated with LH (n = 178, 53.9%) or isolated (n = 156, 46.6%), independent of the use of antiplatelet and/or anticlotting drugs (unpublished data). It is important to note that injection site-related adverse events, such as pain, redness, bruising, and bleeding, are significant barriers to patient adherence to treatment regimens involving multiple daily injections. This is especially important when physicians and/or healthcare providers are not sufficiently experienced or possess insufficient knowledge to provide assistance [28] [29] [30] or when the doctor-patient relationship is unsatisfactory [29] .
To fill this gap, during the last few years an interesting exchange of experiences has developed among patients through various 
EXENATIDE LONG-ACTING ONCE-WEEKLY FORMULATION
Another type of palpable, yet often invisible subcutaneous nodule is the one occurring following subcutaneous shots of long-acting, once-weekly formulation of exenatide (EQW), a glucagon-like peptide-1 receptor agonist (GLP-1 RA) [36] . This adverse event was reported in registration studies, together with other injection site-related adverse events [37] , among which itching was the most common, although its rate appeared to wane over time, from 11.0% between weeks 4 and 6 to 4.6% between weeks 28 and 30 [38] . An informal communication from the DURATION-1 study staff indicated that nodules were generally 0.5-0.75 cm in diameter, and their incidence seemed to decline over time and slowly vanished, even in patients with several earlier similar episodes [37] [38] [39] 
ANTI-TUMOR NECROSIS FACTOR
The anti-tumor necrosis factor (anti-TNF) biologic agents used against Crohn's disease have been associated with a number of injection site reactions, including redness, itching, bruising, pain, or swelling [41] . These have been commonly observed with subcutaneous protein injections even in the combined safety trial [42] [43] [44] . However, once again no published reports are available on anti-TNF-related lipodystrophic injuries similar to those due to insulin injections, and therefore specific studies are warranted in this area also.
CONCLUSIONS AND METHODOLOGICAL CONSIDERATIONS
All of these different types of skin lesions can be confounding, especially when no clear-cut differentiation can be made between well-defined lesions with different morphology and pathogenesis, such as insulin-related LH and LA. Specifically, LH and LA are still occasionally confused [9] , even though the latter is a scarring lesion and is therefore quite different from LH in terms of both morphology (see Fig. 2 ) and pathogenesis. Indeed, while confusing these two lesion types may have been justified back in 2002, when a letter to the editor published in Diabetes Care proposed a three-stage classification for insulin-related LD despite little being admittedly known about the nature and causes of described phenomena [3, 7, 23] . However, given the state of current scientific knowledge, no confusion should be made between lesions having so different an appearance and metabolic consequences.
In conclusion, even today little information is available on possible clinical consequences of local injection-related side-effects of subcutaneous medications against diabetes (exenatide and other GLP-1-RA), acromegaly (pegvisomant), or Crohn's disease (anti-TNF).
Based on evidence showing that insulin shots are the most frequent factors associated to skin lesions, we suggest that precautions recommended for insulin injections may be adopted for all other subcutaneously injected drugs as well. In particular, local damage may be minimized through the use of very short and thin needles and a careful injection site rotation method [45] . However, dedicated studies are needed to support this hypothesis.
Conversely, no cases of LA associated with subcutaneous use of drugs other than insulin have been reported to date. LA lesions are even quite rare in insulin-treated patients, since the most numerous patient series described in the literature adds up to 24 subjects [4] . LA has been suggested to be related to the use of animal insulins [46] , and the prevalence of LA lesions has been noted to have declined considerably following the introduction of new insulin analogs on the market, although some cases of LA have also been reported to be associated with the latter as well.
Given the state of current knowledge, any confusion between LA and LH is no longer justified from a clinical perspective, as insulin has a much higher chance to penetrate into the subcutaneous muscle tissue when injected into areas affected by LA, thus eventually causing more severe hypoglycemic events and at a much higher frequency than that observed with LH.
Prevention of wide glycemic variations and the risk of hypoglycemia is primarily based on patient education with respect to the need for regular injection site rotation and avoidance of areas affected by LA or LH. In fact, we suggest that patients be educated so as to be able to identify LA and LH themselves in order to avoid damaged areas as much as possible [3, 23] . 
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